ATE486613T1 - Mit nucleinsäure complexierte block-copolymere - Google Patents

Mit nucleinsäure complexierte block-copolymere

Info

Publication number
ATE486613T1
ATE486613T1 AT03712331T AT03712331T ATE486613T1 AT E486613 T1 ATE486613 T1 AT E486613T1 AT 03712331 T AT03712331 T AT 03712331T AT 03712331 T AT03712331 T AT 03712331T AT E486613 T1 ATE486613 T1 AT E486613T1
Authority
AT
Austria
Prior art keywords
zwitterionic
copolymer
monomers
polymer
active compound
Prior art date
Application number
AT03712331T
Other languages
English (en)
Inventor
A Lennard Lewis
Steven Armes
Original Assignee
Biocompatibles Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles Uk Ltd filed Critical Biocompatibles Uk Ltd
Application granted granted Critical
Publication of ATE486613T1 publication Critical patent/ATE486613T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT03712331T 2002-03-07 2003-03-07 Mit nucleinsäure complexierte block-copolymere ATE486613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02251605 2002-03-07
PCT/GB2003/000992 WO2003074090A2 (en) 2002-03-07 2003-03-07 Compositions of polymers

Publications (1)

Publication Number Publication Date
ATE486613T1 true ATE486613T1 (de) 2010-11-15

Family

ID=27771938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712331T ATE486613T1 (de) 2002-03-07 2003-03-07 Mit nucleinsäure complexierte block-copolymere

Country Status (6)

Country Link
US (1) US8182802B2 (de)
EP (1) EP1480680B1 (de)
AT (1) ATE486613T1 (de)
AU (1) AU2003217009A1 (de)
DE (1) DE60334779D1 (de)
WO (1) WO2003074090A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
EP1480619B1 (de) * 2002-03-07 2013-08-07 Biocompatibles UK Limited Wirkstoffträger enthaltend amphiphile blockcopolymere
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
EP1592412A1 (de) * 2003-01-31 2005-11-09 Novartis AG Verminderungsregulation der genexpression mit pei/einzelsträngigen oligoribonukleotid-komplexen
EP1590388A2 (de) * 2003-02-05 2005-11-02 Biocompatibles UK Limited Blockcopolymere
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
JP2005234584A (ja) * 2004-02-22 2005-09-02 Rohm & Haas Electronic Materials Llc フォトレジスト組成物
EP3222142A1 (de) 2006-02-28 2017-09-27 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholin-haltige polymerkonjugate und deren herstellung
US20080207822A1 (en) * 2007-02-22 2008-08-28 General Electric Company Composition and associated method
EP2282720B1 (de) * 2008-05-15 2013-09-11 Biocompatibles Uk Ltd. Intrazelluläre antikörper-abgabe
WO2009138472A1 (en) * 2008-05-15 2009-11-19 Biocompatibles Uk Limited Amphiphilic block copolymers for nucleic acid delivery
EP2260873B1 (de) 2009-06-08 2019-07-24 Biocompatibles UK Limited Pcylierung von proteinen
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9393194B2 (en) * 2010-11-23 2016-07-19 Chung Yuan Christian University Biocarrier and method of using the same
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US9309336B2 (en) 2013-11-27 2016-04-12 King Fahd University Of Petroleum And Minerals Synthesis and antiscalant behavior of a novel polyzwitterionic acid
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB201603296D0 (en) 2016-02-25 2016-04-13 Ucl Business Plc Chemotactic,drug-containing polymersomes
GB201604553D0 (en) 2016-03-17 2016-05-04 Ucl Business Plc Fumarate polymersomes
GB201608737D0 (en) 2016-05-18 2016-06-29 Ucl Business Plc Polymersomes
EP3758737A4 (de) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6-antikörper und fusionskonstrukte und konjugate davon
GB201806095D0 (en) 2018-04-13 2018-05-30 Ucl Business Plc Metabolisable pH sensitive polymersomes
CN113646003A (zh) 2019-01-07 2021-11-12 Ucl商业有限公司 多配体官能化的聚合物泡囊
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3238273A1 (en) 2021-11-24 2023-06-01 Giuseppe Battaglia Polymersomes for clearance of amyloid beta and/or tau proteins
EP4646189A1 (de) 2023-01-06 2025-11-12 Vianautis Bio Limited Polymersome zur verabreichung von nukleinsäurefracht

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317178D0 (en) 1993-08-18 1993-10-06 Biocompatibles Ltd Polymer surface coatings
US6291620B1 (en) * 1994-11-09 2001-09-18 E. I. Du Pont De Nemours And Company Polymer synthesis
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
GB9624130D0 (en) 1996-11-20 1997-01-08 Biocompatibles Ltd Biocompatible compositions
CA2294334A1 (en) 1997-06-13 1998-12-17 Adi Eisenberg Compositions for delivery of biological agents and methods for the preparation thereof
AU7836798A (en) 1997-06-13 1998-12-30 University Of Nebraska Board Of Regents Compositions for delivery of biological agents and methods for the preparation thereof
US6258371B1 (en) * 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US6562330B1 (en) 1998-11-13 2003-05-13 Biocompatibles Limited Therapeutic use of polymers
ES2212648T3 (es) 1998-11-13 2004-07-16 Biocompatibles Uk Limited Complejo de poliiones anionicos-cationicos que comprenden un componente monomero dipolar.
GB9924502D0 (en) * 1999-10-15 1999-12-15 Biocompatibles Ltd Polymer blend materials
US6310175B1 (en) * 1999-10-23 2001-10-30 Nippon Shokubai Co., Ltd. Star-shaped block copolymer and production process therefor
AU2001292092A1 (en) 2000-10-06 2002-04-15 Biocompatibles Uk Limited Zwitterionic polymers
WO2003062290A1 (en) 2002-01-16 2003-07-31 Biocompatibles Uk Limited Polymer conjugates
EP1480619B1 (de) 2002-03-07 2013-08-07 Biocompatibles UK Limited Wirkstoffträger enthaltend amphiphile blockcopolymere
GB0301014D0 (en) 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
EP1590388A2 (de) 2003-02-05 2005-11-02 Biocompatibles UK Limited Blockcopolymere

Also Published As

Publication number Publication date
AU2003217009A1 (en) 2003-09-16
EP1480680B1 (de) 2010-11-03
WO2003074090A2 (en) 2003-09-12
WO2003074090A3 (en) 2003-12-18
DE60334779D1 (en) 2010-12-16
US20050163743A1 (en) 2005-07-28
EP1480680A2 (de) 2004-12-01
US8182802B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
ATE486613T1 (de) Mit nucleinsäure complexierte block-copolymere
EP0828779A4 (de) Wasserlösliche polymere und diese enthaltende zusammensetzungen
ES2173370T3 (es) Agente adhesivo y aglutinante para un sistema terapeutico adhesivo y aglutinante.
PT94396A (pt) Processo para a preparacao de copolimeros bloco de poli(oxido de alquileno) que contem fluor e/ou silicone e as suas lentes de contacto
FR2796392B1 (fr) Composition nettoyante comprenant un polymere hydrosoluble ou hydrodispersable
FR2796390B1 (fr) Utilisation d'un polymere amphotere pour traiter une surface dure
CA2349620A1 (en) Use of aliphatic polyamines for reducing oxalate
AU2001235490A1 (en) Cosmetic agent
AU1975295A (en) Antithrombotic agents
SE8800632L (sv) Komposition pa basis av amfotera polymerer och katjoniska polymerer till anvendning for behandling av keratinfibrer
JP2002265336A5 (de)
BR0213655A (pt) Composição e método para o tratamento dos cabelos e uso do polìmero
DK2239269T3 (da) Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
BR0013097A (pt) Utilização de pelo menos um polìmero hidrossolúvel
CA2287375A1 (en) Ampholyte polymers for use in personal care products
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
PT994701E (pt) Copolimero de blocos
CY1105109T1 (el) Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
ES2139931T3 (es) Adhesivo de contacto de uso medico.
AU7808700A (en) Zwitterionic polymer blend materials
TR200200358T2 (tr) Büyüme sonrası herbisitlerden toprağa uygulananlara kadar herbisit maddeler.
EP1539109A4 (de) Blockcopolymer-mizellenzusammensetzung mit verbesserter arzneimittelbeladungskapazität und verzögerter freisetzung
EP1192932A3 (de) Dauerhaftes Haarfrisurgel
DE602004012713D1 (de) Konjugationsreaktionen
FR2852238B1 (fr) Compositions cosmetiques comprenant un copolymere d'acide methacrylique, des particules minerales insolubles et un polymere cationique et leurs utilisations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties